Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Vixotrigine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A known ✓ | Q15858 | 1/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 18/20 | 1.00 |
| ▸ | SCN3A | Q9NY46 | 10/20 | 1.00 |
| ▸ | SCN1A | P35498 | 1/20 | 1.00 |
| ▸ | SCN4A | P35499 | 1/20 | 1.00 |
| ▸ | SCN7A | Q01118 | 1/20 | 1.00 |
| ▸ | SCN5A | Q14524 | 1/20 | 1.00 |
| ▸ | SCN2A | Q99250 | 1/20 | 1.00 |
| ▸ | SCN8A | Q9UQD0 | 1/20 | 1.00 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.98 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.98 |
| ▸ | MAOB | P27338 | 1/20 | 0.98 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.98 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Vixotrigine SCHEMBL311437 | 1.00 | KCNH2 (1.00) | KCNH2SCN3ASCN1ASCN4ASCN7A | |
| Vixotrigine SCHEMBL862301 | 1.00 | KCNH2 (1.00) | KCNH2SCN3ASCN1ASCN4ASCN7A | |
| Vixotrigine SCHEMBL311438 | 1.00 | KCNH2 (1.00) | KCNH2SCN3ASCN1ASCN4ASCN7A | |
| Vixotrigine SCHEMBL29385387 | 1.00 | KCNH2 (1.00) | KCNH2SCN3ASCN1ASCN4ASCN7A | |
| Vixotrigine SCHEMBL840590 | 1.00 | KCNH2 (1.00) | KCNH2SCN3ASCN1ASCN4ASCN7A | |
| Vixotrigine SCHEMBL2831660 | 1.00 | KCNH2 (1.00) | KCNH2SCN3ASCN1ASCN4ASCN7A | |
| Vixotrigine SCHEMBL862457 | 1.00 | KCNH2 (1.00) | KCNH2SCN3ASCN1ASCN4ASCN7A | |
| Vixotrigine SCHEMBL840179 | 0.99 | KCNH2 (1.00) | KCNH2SCN3ASCN1ASCN4ASCN7A | |
| Vixotrigine SCHEMBL20562288 | 0.99 | KCNH2 (1.00) | KCNH2SCN3ASCN1ASCN4ASCN7A | |
| Vixotrigine SCHEMBL4446697 | 0.99 | KCNH2 (1.00) | KCNH2SCN3ASCN1ASCN4ASCN7A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 504 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025264860-A2 | METHODS OF TREATING POST-COVID AIRWAY DISEASE | YALE UNIVERSITY (US) | 2025-12-26 | — | — | WO | claimed |
| WO-2025106656-A1 | METHODS OF PREVENTING OR REDUCING CARTILAGE LOSS AND/OR JOINT DAMAGE USING NAV 1.7 INHIBITORS | YALE UNIVERSITY (US) | 2025-05-22 | — | — | WO | claimed |
| CN-118909916-A | Colonocytes and methods of making and using the same | 儿童医院医学中心 | 2024-11-08 | — | — | CN | claimed |
| CN-118192242-A | A scanning control system that is used for sample detection system's robust active disturbance rejection | 中国科学院上海高等研究院 | 2024-06-14 | — | — | CN | claimed |
| US-20240148745-A1 | COMPOUNDS FOR USE IN PROGRESSIVE MULTIPLE SCLEROSIS | FONDAZIONE CENTRO SAN RAFFAELE (IT) | 2024-05-09 | — | — | US | claimed |
| CN-117899072-A | Application of sodium ion channel inhibitor in preparation of medicine for promoting wound healing | 广州市朝利良生物科技有限公司 | 2024-04-19 | — | — | CN | claimed |
| CN-117431260-A | Molecular marker of rice mesocotyl gene GSK2 allele, primer and method for detecting molecular marker | 常熟市农业科学研究所 | 2024-01-23 | — | — | CN | claimed |
| EP-4304719-A1 | COMPOUNDS FOR USE IN PROGRESSIVE MULTIPLE SCLEROSIS | Fondazione Centro San Raffaele (IT) | 2024-01-17 | — | — | EP | claimed |
| WO-2023161308-A1 | KINASE INHIBITORS FOR USE IN TREATING ALEXANDER DISEASE | UNIVERSITY OF PLYMOUTH (GB) | 2023-08-31 | — | — | WO | claimed |
| US-20230081195-A1 | METHODS OF CONTROLLING GRAIN SIZE AND WEIGHT | INSTITUTE OF GENETICS AND DEVELOPMENTAL BIOLOGY CHINESE ACADEMY OF SCIENCES (CN) | 2023-03-16 | — | — | US | claimed |
| US-8093268-B2 | Pharmaceutical compositions comprising 2-methoxy-5-(5-trifluoromethyl-tetrazol-1-yl-benzyl)-(2S-phenylpiperidin-3S-yl-) | GLAXO GROUP LIMITED (GB) | 2012-01-10 | — | — | US | claimed |
| EP-2117535-B1 | PHARMACEUTICAL COMPOSITIONS COMPRISING NK1 RECEPTOR ANTAGONISTS AND SODIUM CHANNEL BLOCKERS | GLAXO GROUP LTD (GB) | 2011-10-26 | — | — | EP | claimed |
| WO-2011029762-A1 | PROCESS FOR PREPARING ALPHA-CARBOXAMIDE DERIVATIVES | Convergence Pharmaceuticals Limited (GB) | 2011-03-17 | — | — | WO | claimed |
| US-7655693-B2 | Compounds | GLAXO GROUP LIMITED (GB) | 2010-02-02 | — | — | US | claimed |
| US-20090318530-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING NK1 RECEPTOR ANTAGONISTS AND SODIUM CHANNEL BLOCKERS | GLAXO GROUP LIMITED (GB) | 2009-12-24 | — | — | US | claimed |
| EP-2117535-A1 | NOVEL PHARMACEUTICAL COMPOSITIONS | Glaxo Group Limited (GB) | 2009-11-18 | — | — | EP | claimed |
| US-20080306122-A1 | Novel Compounds | Convergence Pharmaceuticals Limited (GB) | 2008-12-11 | — | — | US | claimed |
| WO-2008090116-A1 | NOVEL PHARMACEUTICAL COMPOSITIONS | GLAXO GROUP LIMITED (GB) | 2008-07-31 | — | — | WO | claimed |
| EP-1943216-A1 | PROLINAMIDE DERIVATIVES AS SODIUM CHANNEL MODULATORS | GLAXO GROUP LIMITED (GB) | 2008-07-16 | — | — | EP | claimed |
| WO-2007042250-A1 | PROLINAMIDE DERIVATIVES AS SODIUM CHANNEL MODULATORS | GLAXO GROUP LIMITED (GB) | 2007-04-19 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090318530-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING NK1 RECEPTOR ANTAGONISTS AND SODIUM CHANNEL BLOCKERS | HCRTR1, TACR2, CNR1 | SCN9A 157/4885KCNH2 7/4885SCN3A 45/4885 |
| US-20080306122-A1 | Novel Compounds | CYP11B1, CYP11B2, CYP46A1 | SCN9A 1641/4885KCNH2 3313/4885SCN3A 2352/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.